(UroToday.com) The 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in New Orleans, LA, was host to a Radiopharmaceutical Therapy Trials with Dosimetry session. Dr.

ASCO 2025 circulating and tumor microenvironment determinants of patient response in the Checkmate 9ER trial, nivolumab and cabozantinib in advanced renal cell carcinoma (RCC).

ASCO 2025 HIF-2α targeting as a new frontier in renal cell cancer (RCC) therapy, Von Hippel-Lindau (VHL) gene mutation, LITESPARK-005, metastatic clear cell RCC. belzutifan.

SNMMI 2025, post-177Lu therapy, WB SPECT/CT, WB SPECT/CT Studies Post Lu 177 Therapy, 177Lu-PSMA SPECT, StarGuide scanner, 177Lu-PSMA-617 radiopharmaceutical therapy.

Women who complain of bladder pain and urinary urgency and frequency wait years to receive the label of interstitial cystitis (IC), an "orphan disease" which has no known cause or cure. The current ...

This study aims to evaluate the long-term outcomes of the novel "three horseshoe-like incision" (3-HSI) technique for holmium laser enucleation of the prostate (HoLEP) compared to the traditional ...